National Research Corp. Downgraded by Zacks to Underperform (NRCIB)
National Research Corp. (NASDAQ:NRCIB) was downgraded by Zacks from a “neutral” rating to an “underperform” rating in a note issued to investors on Monday, Stock Ratings Network.com reports. They currently have a $35.70 price objective on the stock. Zacks‘ target price points to a potential downside of 5.00% from the stock’s previous close.
National Research Corp. (NASDAQ:NRCIB) traded down 6.03% on Monday, hitting $37.58. 5,417 shares of the company’s stock traded hands. National Research Corp. has a 52 week low of $18.24 and a 52 week high of $64.36. The stock’s 50-day moving average is $36.44 and its 200-day moving average is $32.95. The company has a market cap of $907.3 million and a price-to-earnings ratio of 63.58.
National Research Corp. is a healthcare company in the Health Care Services industry.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.